Morepen Labs adds blockbuster Rivaroxaban, Vildagliptin, UDCA to API portfolio Farhat Nasim14 Oct 2019 1:36 PM ISTWhile two products Rivaroxaban and Vildagliptin will augment Morepen Lab's presence in the cardiac and diabetic segments respectively, the third...
AstraZeneca India bags DCGI marketing nod for QTERN-once-daily anti-diabetes drug Medical Dialogues Bureau27 Sept 2019 11:54 AM IST26 September 2019: AstraZeneca Pharma India Limited (AstraZeneca India) announced that it has received Import & Market permission for QTERN®...